1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Primary Immune Deficiency (PID)-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Primary Immune Deficiency (PID)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Primary Immune Deficiency (PID). This report provides information on the therapeutic development based on the Primary Immune Deficiency (PID) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Primary Immune Deficiency (PID) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Primary Immune Deficiency (PID) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Primary Immune Deficiency (PID)
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Primary Immune Deficiency (PID)-Pipeline Insights, 2014
Table of Contents
- Primary Immune Deficiency (PID) Overview
- Primary Immune Deficiency (PID) Pipeline Therapeutics
- Primary Immune Deficiency (PID) Therapeutics under Development by Companies
- Primary Immune Deficiency (PID) Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Primary Immune Deficiency (PID) Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Primary Immune Deficiency (PID) Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Primary Immune Deficiency (PID) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Primary Immune Deficiency (PID) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Primary Immune Deficiency (PID) - Discontinued Products
- Primary Immune Deficiency (PID) - Dormant Products
- Companies Involved in Therapeutics Development for Primary Immune Deficiency (PID)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Primary Immune Deficiency (PID), 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Primary Immune Deficiency (PID) Assessment by Monotherapy Products
- Primary Immune Deficiency (PID) Assessment by Combination Products
- Primary Immune Deficiency (PID) Assessment by Route of Administration
- Primary Immune Deficiency (PID) Assessment by Stage and Route of Administration
- Primary Immune Deficiency (PID) Assessment by Molecule Type
- Primary Immune Deficiency (PID) Assessment by Stage and Molecule Type
- Primary Immune Deficiency (PID) Therapeutics - Discontinued Products
- Primary Immune Deficiency (PID) Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Primary Immune Deficiency (PID), 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Primary Immune Deficiency (PID) Assessment by Monotherapy Products
- Primary Immune Deficiency (PID) Assessment by Combination Products
- Primary Immune Deficiency (PID) Assessment by Route of Administration
- Primary Immune Deficiency (PID) Assessment by Stage and Route of Administration
- Primary Immune Deficiency (PID) Assessment by Molecule Type
- Primary Immune Deficiency (PID) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Europe Genetic Testing Market

Europe Genetic Testing Market

  • $ 3850
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The European genetic testing market accounted for USD 1.13 million in 2015 and is estimated to reach USD 1.22 billion in 2016. The market value is expected to reach USD 1.81 billion by 2021, growing at ...

Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials

Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials

  • $ 2995
  • Industry report
  • February 2017
  • by Currentpartnering

Summary Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals ...

Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2016

Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2016" provides ...


Download Unlimited Documents from Trusted Public Sources

Cardiovascular Disease Statistics in the US

  • February 2017
    33 pages
  • Cardiovascular ...  

    Therapy  

  • United States  

View report >

Digestive System Disorder and Obesity Statistics in the US

  • February 2017
    150 pages
  • Digestive Syste...  

    Obesity  

    Diabetes  

  • United States  

View report >

Digestive System Disorder and Obesity Statistics in the US

  • February 2017
    150 pages
  • Digestive Syste...  

    Obesity  

    Diabetes  

  • United States  

View report >

Related Market Segments :

Genetic Disorder
Infectious Disease

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.